EKF Diagnostics Holdings
plc
("EKF" or
the "Company")
Posting of Annual Report &
Accounts
and
Notice of AGM
EKF Diagnostics Holdings
plc (AIM: EKF), the AIM-listed global
diagnostics business, confirms that the Annual Report and Accounts for the year ended
31 December 2023 (the "Annual Report") and the Notice of the 2024
Annual General Meeting ("AGM") have
now been published on the Company's website via
https://www.ekfdiagnostics.com/documents-reports.html
.
The Annual Report,
Notice of AGM and details for voting by
proxy have all
been posted today to shareholders who have
not consented to receive electronic communications.
The AGM will be held at 11:00 am on
14 May 2024 at Harwood Capital LLP, 6 Stratton Street Mayfair,
London W1J 8LD and will consider the resolutions set out in the
Notice of AGM.
The Company is providing a facility
for shareholders to listen in to the AGM either online or
telephonically (in a non-voting capacity) and there will be an
opportunity for shareholders to ask questions. In order to
facilitate the process, the Directors would request that
shareholders register for the meeting and submit questions in
advance, before 11:00 am on Friday 10 May 2024. To register for
dial-in details and to submit any questions please contact Walbrook
PR via email at ekf@walbrookpr.com or
call +44 (0)20 7933 8780.
Proxy voting
Shareholders will not automatically
receive a hard copy form of proxy for the AGM in the post. Instead,
shareholders will be able to vote electronically using the
link available via https://www.signalshares.com
and selecting the "Proxy Voting" link, or lodging
a proxy appointment by using the CREST Proxy Voting
Service.
Alternatively, shareholders may
request a hard copy form of proxy directly by calling the
Registrars, Link Group, on Tel: 0371 664 0391. Calls are charged at
the standard geographic rate and will vary by provider. Calls
outside the United Kingdom will be charged at the applicable
international rate. Lines are open between 09:00 - 17:30, Monday to
Friday excluding public holidays in England and Wales.
|
EKF
Diagnostics Holdings plc
|
www.ekfdiagnostics.com
|
|
Julian Baines, Executive Chair /
Stephen Young, CFO
|
Tel:
+44 (0)29 2071
0570
|
|
|
|
|
Singer Capital Markets (Nominated
Adviser & Broker)
|
Tel: +44
(0)20 7496 3000
|
|
Aubrey Powell / Oliver
Platts
|
|
|
|
|
|
Walbrook PR Limited
|
Tel: +44 (0)20 7933 8780
or ekf@walbrookpr.com
|
|
Paul McManus / Alice
Woodings
|
Mob: +44
(0)7980 541 893 / +44 (0)7407 804 654
|
|
|
|
| |
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global
diagnostics business focussed on:
·
Point-of-Care analysers in the
key areas of Hematology and Diabetes, as well as Central Laboratory products including
clinical chemistry reagents, analysers and centrifuges.
·
Life
Sciences services provide specialist
manufacture of enzymes and custom products for use in diagnostic
food and industrial applications, as well as other higher value
Contract Manufacturing
services
EKF has headquarters in Penarth
(near Cardiff) and operates five manufacturing sites across the US
and Germany, selling into over 120 countries world-wide.